Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

IMMP

Immutep (IMMP)

Immutep Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMMP
DateTimeSourceHeadlineSymbolCompany
01/06/20257:00AMGlobeNewswire Inc.Patient Enrolment Completed for INSIGHT-003NASDAQ:IMMPImmutep Ltd
12/17/20247:00AMGlobeNewswire Inc.Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761NASDAQ:IMMPImmutep Ltd
12/16/20247:00AMGlobeNewswire Inc.Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IINASDAQ:IMMPImmutep Ltd
12/12/20242:33PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
12/12/20247:15AMGlobeNewswire Inc.Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024NASDAQ:IMMPImmutep Ltd
12/10/20244:26PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
12/10/20247:00AMGlobeNewswire Inc.Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
11/14/20247:15AMGlobeNewswire Inc.Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
11/14/20247:00AMGlobeNewswire Inc.Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual MeetingNASDAQ:IMMPImmutep Ltd
10/29/20247:00AMGlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY25NASDAQ:IMMPImmutep Ltd
10/28/20247:00AMGlobeNewswire Inc.Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024NASDAQ:IMMPImmutep Ltd
10/17/20247:00AMGlobeNewswire Inc.Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of TrialNASDAQ:IMMPImmutep Ltd
10/10/20247:00AMGlobeNewswire Inc.Immutep to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:IMMPImmutep Ltd
10/03/20247:00AMGlobeNewswire Inc.Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
09/24/20247:00AMGlobeNewswire Inc.Immutep Receives A$3.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
09/24/20245:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
09/18/20247:00AMGlobeNewswire Inc.New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
09/16/20247:00AMGlobeNewswire Inc.Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerNASDAQ:IMMPImmutep Ltd
09/09/20248:54PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
08/20/20247:00AMGlobeNewswire Inc.Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024NASDAQ:IMMPImmutep Ltd
08/14/20247:00AMGlobeNewswire Inc.Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 AntibodyNASDAQ:IMMPImmutep Ltd
08/07/20247:00AMGlobeNewswire Inc.Immutep to Participate in Upcoming Investor ConferencesNASDAQ:IMMPImmutep Ltd
07/31/20247:00AMGlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY24NASDAQ:IMMPImmutep Ltd
07/22/20247:00AMGlobeNewswire Inc.Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
07/17/20247:00AMGlobeNewswire Inc.Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune DiseasesNASDAQ:IMMPImmutep Ltd
07/11/20245:40PMGlobeNewswire Inc.Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 ExpressionNASDAQ:IMMPImmutep Ltd
07/03/20247:00AMGlobeNewswire Inc.Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical ResultsNASDAQ:IMMPImmutep Ltd
06/25/20247:00AMGlobeNewswire Inc.Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for CancerNASDAQ:IMMPImmutep Ltd
06/05/20245:00AMGlobeNewswire Inc.Immutep successfully completes institutional placement and institutional component of entitlement offerNASDAQ:IMMPImmutep Ltd
06/04/20246:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
 Showing the most relevant articles for your search:NASDAQ:IMMP